13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001615982
Total reported value
$3.3B
$3.3B
38 檔
26.8%
At the close of Q3 2024, Venrock Adviser, LLC disclosed equity holdings valued at approximately $3.3B, spread across 38 reported holdings.
In Q3 2024, Venrock Adviser, LLC displayed an active expansion posture, initiating 4 new positions and adding to 5 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including APGE, OCUL, ELVN) accounted for 26.8% of total reported equity market value during Q3 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics Inc | Stock-Other | 26.13% | +7.50% | — | |
| 2 | OCUL | Ocular Therapeutix Inc | Stock-Other | 5.82% | -0.19% | — | |
| 3 | ELVN | Enliven Therapeutics Inc | Stock-Other | 5.39% | -1.72% | — | |
| 4 | VRDN | Viridian Therapeutics Inc | Stock-Other | 4.63% | -1.02% | +0.00% | |
| 5 | APLT | Applied Therapeutics Inc | Stock-Other | 4.37% | — | +2.96% | |
| 6 | SYRE | Spyre Therapeutics Inc | Stock-Other | 4.14% | +1.10% | — | |
| 7 | DYN | Dyne Therapeutics Inc | Stock-Other | 4.09% | -0.01% | — | |
| 8 | ORKA | Oruka Therapeutics Inc | Stock-Other | 3.96% | +4.37% | — | |
| 9 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 3.79% | -4.86% | EXIT | |
| 10 | PHVS | Pharvaris N.V. | Stock-Other | 3.29% | — | — | |
| 11 | COGT | Cogent Biosciences Inc | Stock-Other | 3.22% | -0.94% | — | |
| 12 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.50% | -0.21% | -16.71% | |
| 13 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 2.49% | — | — | |
| 14 | ✓ | Merus N V | Stock-Other | 2.38% | — | -28.12% | |
| 15 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 2.36% | -0.62% | — | |
| 16 | ERAS | Erasca Inc | Stock-Other | 2.32% | +0.05% | — | |
| 17 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.13% | — | — | |
| 18 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.99% | — | -4.16% | |
| 19 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.49% | — | — | |
| 20 | AQST | Aquestive Therapeutics Inc | Stock-Other | 1.45% | — | — | |
| 21 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.40% | — | -45.00% | |
| 22 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 1.30% | +0.21% | — | |
| 23 | ✓ | Engene Holdings Inc | Stock-Other | 1.23% | -1.21% | EXIT | |
| 24 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 1.21% | +0.03% | — | |
| 25 | ✓ | Mersana Therapeutics Inc | Stock-Other | 1.12% | — | — | |
| 26 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.95% | — | — | |
| 27 | ABVX | Abivax Sa-adr | Stock-Other | 0.81% | — | — | |
| 28 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.60% | — | +0.00% | |
| 29 | ARVN | Arvinas Inc | Stock-Other | 0.59% | — | -27.61% | |
| 30 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 0.54% | — | — | |
| 31 | IPSC | Century Therapeutics Inc | Stock-Other | 0.48% | -0.08% | — | |
| 32 | ✓ | Zura Bio LTD | Stock-Other | 0.43% | -0.28% | -66.41% | |
| 33 | ✓ | Stock-Other | 0.39% | — | — | ||
| 34 | CABA | Cabaletta Bio Inc | Stock-Other | 0.39% | — | — | |
| 35 | ✓ | Casi Pharmaceuticals Inc | Stock-Other | 0.32% | — | +783.96% | |
| 36 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.16% | — | — | |
| 37 | TIL | Instil Bio Inc | Stock-Other | 0.12% | — | — | |
| 38 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.04% | -1.00% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics Inc | +4.9% | — | Unchanged |
| 2 | ORKA | Oruka Therapeutics Inc | +4% | NEW | New buy |
| 3 | APLT | Applied Therapeutics Inc | +1.5% | +2.96% | Add |
| 4 | VRDN | Viridian Therapeutics Inc | +1.4% | +0.00% | Add |
| 5 | ARTV | Artiva Biotherapeutics Inc | +1.3% | NEW | New buy |
| 6 | AQST | Aquestive Therapeutics Inc | +0.5% | — | Unchanged |
| 7 | ORIC | Oric Pharmaceuticals Inc | +0.4% | — | Unchanged |
| 8 | ✓ | Casi Pharmaceuticals Inc | +0.3% | +783.96% | Add |
| 9 | PRAX | Praxis Precision Medicines I | +0.3% | — | Unchanged |
| 10 | OCUL | Ocular Therapeutix Inc | +0.3% | — | Unchanged |
| 11 | COGT | Cogent Biosciences Inc | +0.2% | — | Unchanged |
| 12 | SYRE | Spyre Therapeutics Inc | +0.1% | — | Unchanged |
| 13 | TIL | Instil Bio Inc | +0.1% | NEW | New buy |
| 14 | TENX | Tenax Therapeutics Inc | 0% | NEW | New buy |
| 15 | 430 | Terns Pharmaceuticals Inc | 0% | — | Unchanged |
| 16 | TRVI | Trevi Therapeutics Inc | -0.1% | +0.00% | Add |
| 17 | ✓ | -0.1% | — | Unchanged | |
| 18 | CATBUSD | Astria Therapeutics Inc | -0.1% | -4.16% | Trim |
| 19 | AVU0 | Adverum Biotechnologies Inc | -0.1% | — | Unchanged |
| 20 | ERAS | Erasca Inc | -0.1% | — | Unchanged |
| 21 | TNYA | Tenaya Therapeutics Inc | -0.2% | — | Unchanged |
| 22 | ABIOEUR | Arca Biopharma Inc | -0.2% | EXIT | Sold out |
| 23 | ABVX | Abivax Sa-adr | -0.3% | — | Unchanged |
| 24 | CGEM | Cullinan Therapeutics Inc | -0.3% | — | Unchanged |
| 25 | TSHA | Taysha Gene Therapies Inc | -0.3% | — | Unchanged |
| 26 | ✓ | Mersana Therapeutics Inc | -0.3% | — | Unchanged |
| 27 | CABA | Cabaletta Bio Inc | -0.4% | — | Unchanged |
| 28 | IPSC | Century Therapeutics Inc | -0.4% | — | Unchanged |
| 29 | ARVN | Arvinas Inc | -0.5% | -27.61% | Trim |
| 30 | ✓ | Engene Holdings Inc | -0.5% | +26.18% | Add |
| 31 | ELVN | Enliven Therapeutics Inc | -0.6% | — | Unchanged |
| 32 | EWTX | Edgewise Therapeutics Inc | -0.7% | -45.00% | Trim |
| 33 | PHVS | Pharvaris N.V. | -0.8% | — | Unchanged |
| 34 | DYN | Dyne Therapeutics Inc | -0.8% | — | Unchanged |
| 35 | 4XC1 | Kalvista Pharmaceuticals Inc | -0.9% | — | Unchanged |
| 36 | ✓ | Zura Bio LTD | -0.9% | -66.41% | Trim |
| 37 | DNTH | Dianthus Therapeutics Inc | -1% | -16.71% | Trim |
| 38 | ✓ | Merus N V | -2.4% | -28.12% | Trim |
| 39 | FDMT | 4d Molecular Therapeutics In | -3.4% | — | Unchanged |
According to official SEC Form 13F filings, Venrock Adviser, LLC reported a total U.S. public equity portfolio value of $3.3B across 38 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
ORKA
市值: $75.6M
Top Position Liquidated / Trimmed
ABIOEUR
前期市值: $3.3M
During Q3 2024, Venrock Adviser, LLC's top holdings by market value included APGE (26.1%)、OCUL (5.8%)、ELVN (5.4%). The largest single position, APGE, represented 26.1% of total portfolio value.
In Q3 2024, Venrock Adviser, LLC made 16 total portfolio adjustments, initiating 4 new buys, adding to 5 positions, trimming 6 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.